Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

35 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Melanomas with concurrent BRAF non-p.V600 and NF1 loss-of-function mutations are targetable by BRAF/MEK inhibitor combination therapy.
Rajkumar S, Berry D, Heney KA, Strong C, Ramsay L, Lajoie M, Alkallas R, Nguyen TT, Thomson C, Ahanfeshar-Adams M, Dankner M, Petrella T, Rose AAN, Siegel PM, Watson IR. Rajkumar S, et al. Among authors: dankner m. Cell Rep. 2022 Apr 5;39(1):110634. doi: 10.1016/j.celrep.2022.110634. Cell Rep. 2022. PMID: 35385748 Free article.
Comment on 'Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study'.
Dankner M, Rose AAN. Dankner M, et al. Br J Cancer. 2018 May;118(9):1276-1277. doi: 10.1038/s41416-018-0012-2. Epub 2018 Mar 22. Br J Cancer. 2018. PMID: 29563631 Free PMC article. No abstract available.
BRAF Mutation Class and Clinical Outcomes-Letter.
Dankner M, Rose AAN. Dankner M, et al. Clin Cancer Res. 2019 May 15;25(10):3188. doi: 10.1158/1078-0432.CCR-19-0080. Clin Cancer Res. 2019. PMID: 31092612 No abstract available.
CCN3/Nephroblastoma Overexpressed Is a Functional Mediator of Prostate Cancer Bone Metastasis That Is Associated with Poor Patient Prognosis.
Dankner M, Ouellet V, Communal L, Schmitt E, Perkins D, Annis MG, Barrès V, Caron C, Mes-Masson AM, Saad F, Siegel PM; Canadian Prostate Cancer Biomarker Network. Dankner M, et al. Am J Pathol. 2019 Jul;189(7):1451-1461. doi: 10.1016/j.ajpath.2019.04.006. Epub 2019 Jun 12. Am J Pathol. 2019. PMID: 31202437 Free article.
p66ShcA functions as a contextual promoter of breast cancer metastasis.
Lewis K, Kiepas A, Hudson J, Senecal J, Ha JR, Voorand E, Annis MG, Sabourin V, Ahn R, La Selva R, Tabariès S, Hsu BE, Siegel MJ, Dankner M, Canedo EC, Lajoie M, Watson IR, Brown CM, Siegel PM, Ursini-Siegel J. Lewis K, et al. Among authors: dankner m. Breast Cancer Res. 2020 Jan 15;22(1):7. doi: 10.1186/s13058-020-1245-6. Breast Cancer Res. 2020. PMID: 31941526 Free PMC article.
Chemogenomic profiling of breast cancer patient-derived xenografts reveals targetable vulnerabilities for difficult-to-treat tumors.
Savage P, Pacis A, Kuasne H, Liu L, Lai D, Wan A, Dankner M, Martinez C, Muñoz-Ramos V, Pilon V, Monast A, Zhao H, Souleimanova M, Annis MG, Aguilar-Mahecha A, Lafleur J, Bertos NR, Asselah J, Bouganim N, Petrecca K, Siegel PM, Omeroglu A, Shah SP, Aparicio S, Basik M, Meterissian S, Park M. Savage P, et al. Among authors: dankner m. Commun Biol. 2020 Jun 16;3(1):310. doi: 10.1038/s42003-020-1042-x. Commun Biol. 2020. PMID: 32546838 Free PMC article.
35 results